Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aligos TherapeuticsALGS +2.07%42 Cash-to-Debt is 8.67 as of Jun. 2026, which is 21% below its 10-year median of 10.92. GuruFocus rates ALGS with a GF Score™ of 42/100 and a GF Value™ of $34.40 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,401 Biotechnology companies, Aligos Therapeutics ranks better than 53.32% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Aligos Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was 8.67.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Aligos Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Aligos Therapeutics's Cash-to-Debt or its related term are showing as below:
ALGS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 5.25 Med: 10.92 Max: 19.5
Current: 8.67
During the past 8 years, Aligos Therapeutics's highest Cash to Debt Ratio was 19.50. The lowest was 5.25. And the median was 10.92.
ALGS's Cash-to-Debt is ranked better than 53.32% of 1401
companies
in the Biotechnology industry
Industry Median: 6.43
vs ALGS: 8.67
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Aligos Therapeutics Cash-to-Debt Related Terms
Aligos Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Aligos Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Aligos Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aligos Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aligos Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Aligos Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aligos Therapeutics (ALGS) has a Cash-to-Debt of 8.67 as of Jun. 2026. This is 21% below median its historical median of 10.92. Over the past decade, Aligos Therapeutics' Cash-to-Debt has ranged from 5.25 to 19.50. According to the industry distribution chart, Aligos Therapeutics ranks #654 out of 1401 companies in the Biotechnology industry, placing it in the top 46.7%.
Is Aligos Therapeutics' Cash-to-Debt too high?
Aligos Therapeutics' current Cash-to-Debt of 8.67 is 21% below median its 10-year median of 10.92. Over the past 10 years, this metric has ranged from a low of 5.25 to a high of 19.50. The Biotechnology industry median Cash-to-Debt is 6.43. Aligos Therapeutics' value of 8.67 is 34.8% above this industry median. Based on the distribution chart, Aligos Therapeutics ranks #654 out of 1401 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Aligos Therapeutics has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' Cash-to-Debt compare to CRVO and PVCT?
According to the Biotechnology industry distribution chart, Aligos Therapeutics ranks #654 out of 1401 companies for Cash-to-Debt. This puts Aligos Therapeutics in the upper half of its industry. The industry median Cash-to-Debt is 6.43. Aligos Therapeutics' value of 8.67 is 34.8% above this benchmark. Historically, Aligos Therapeutics' own Cash-to-Debt has ranged from 5.25 to 19.50 over the past decade. While the company's 10-year median is 10.92 vs. the industry median of 6.43, Aligos Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.43, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aligos Therapeutics's current Cash-to-Debt of 8.67 is 34.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aligos Therapeutics's current Cash-to-Debt is 8.67, which is 21% below median its own 10-year median of 10.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aligos Therapeutics (ALGS) is currently considered Possible Value Trap. The stock's GF Value™ is $34.40, compared to a current price of $6.89 — trading 80% below its estimated fair value. The current Cash-to-Debt is 8.67, which is 21% below median its 10-year median of 10.92 and 34.8% above the Biotechnology industry median of 6.43. Aligos Therapeutics' overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Aligos Therapeutics (ALGS), the current Cash-to-Debt is 8.67 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aligos Therapeutics (ALGS) Overvalued in 2026?
Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be undervalued.
The current stock price of $6.89 is trading 80% below its estimated GF Value™ of $34.40.
GuruFocus considers Aligos Therapeutics to be Possible Value Trap.
Key valuation signals for ALGS:
Cash-to-Debt: 8.67 (21% below median its 10-year median of 10.92)
GF Value™: $34.40 vs. price of $6.89 (80% below fair value)
Industry Position: 34.8% above the Biotechnology median (#654 of 1401)
No single metric tells the full story. See the ALGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
42GF Score
Get the complete analysis for ALGS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALGS has been successfully added to your 
